GPR35 and inflammatory bowel disease: The findings from our study highlight the potential of GPR35 agonists to provide non–opioid-based analgesia in GI diseases, such as IBS and IBD, because of their ability to prevent neurogenic colonic afferent activation, mechanosensitisation, and colonic contractility through the inhibition of SP release.